Trial Profile
To compare the effects of Dabigatran,Rivaroxaban and Apixaban on plasma fibrinolysis in patients with non valvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- 01 Dec 2016 New trial record